Summary of COVID-19 mebendazole studies

1. El-Tanani et al., Phase II, Double-Blinded, Randomized, Placebo-Controlled Clinical Trial Investigating the Efficacy of Mebendazole in the Management of Symptomatic COVID-19 Patients

69 patient mebendazole early treatment RCT: 85% improved viral clearance (p=0.04).
RCT 69 outpatients in Jordan, showing improved viral clearance and CRP with mebendazole. Authors note that mebendazole, like ivermectin, has been shown to have antiviral activity against multiple viruses.
May 2023, Pharmaceuticals, https://www.mdpi.com/1424-8247/16/6/799, https://c19p.org/eltananimb

2. Galal et al., The Use of Mebendazole in COVID-19 Patients: An Observational Retrospective Single Center Study

157 patient mebendazole late treatment study: 51% lower mortality (p=0.35), 63% lower ventilation (p=0.3), and 30% shorter hospitalization (p=0.001).
Retrospective 157 inpatients and 185 outpatients, showing improved recovery with mebendazole. For outpatients, the treatment group was younger (40 vs. 48). Mebendazole was offered to patients when ivermectin/HCQ were unavailable. The outpatient and inpatient results are listed separately [Galal, Galal].
Dec 2022, Advances in Virology, https://www.hindawi.com/journals/av/2022/3014686/, https://c19p.org/galal2

3. Galal et al., The Use of Mebendazole in COVID-19 Patients: An Observational Retrospective Single Center Study

185 patient mebendazole early treatment study: 52% lower hospitalization (p=0.33) and 43% faster recovery (p=0.001).
Retrospective 157 inpatients and 185 outpatients, showing improved recovery with mebendazole. For outpatients, the treatment group was younger (40 vs. 48). Mebendazole was offered to patients when ivermectin/HCQ were unavailable. The outpatient and inpatient results are listed separately [Galal, Galal].
Dec 2022, Advances in Virology, https://www.hindawi.com/journals/av/2022/3014686/, https://c19p.org/galalmb